Physician profile
Kenan Qin
NPI 1679623615
$5,036.28
in general payments reported to CMS, 2019-2025
47 companies · $736 in 2025
The $736 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $65.50 · 2021: $556 · 2022: $1,002 · 2023: $1,078 · 2024: $1,174 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,988.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $636.81 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $409.57 | 2021-2023 | Qelbree |
| Glaxosmithkline, LLC. | $387.39 | 2019-2025 | Rotarix, Bexsero, Pediarix |
| Ironshore Pharmaceuticals INC. | $372.02 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $272.20 | 2021-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Insulet Corporation | $236.31 | 2019-2024 | Omnipod |
| Tris Pharma INC | $196.63 | 2019-2025 | Dyanavel Xr |
| Xeris Pharmaceuticals, INC. | $169.23 | 2021-2025 | Gvoke Hypopen |
| Tolmar, INC. | $166.57 | 2023-2025 | Fensolvi |
| Alexion Pharmaceuticals, INC. | $164.30 | 2019-2024 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $130.53 | 2021-2024 | Flumist Quadrivalent |
| Abbvie INC. | $118.40 | 2019-2025 | |
| Dexcom, INC. | $113.11 | 2019-2024 | Dexcom G6 Transmitter |
| Alk-Abello, INC | $107.80 | 2025 | Neffy, Grastek, Ragwitek |
| Kyowa Kirin, INC. | $106.44 | 2023-2025 | Crysvita |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $102.90 | 2024-2025 | |
| Sanofi Pasteur INC. | $102.55 | 2021-2023 | |
| Ascendis Pharma Endocrinology INC | $99.88 | 2023-2024 | |
| Zealand Pharma US, INC. | $96.95 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $89.90 | 2025 | Jornay Pm |
| Seqirus USA INC | $86.71 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent, Fluad Quadrivalent |
| Azurity Pharmaceuticals, INC. | $86.18 | 2023-2024 | Triptodur, Triptodur |
| Lilly USA, LLC | $64.22 | 2019-2023 | Baqsimi |
| Vertical Pharmaceuticals, LLC | $61.39 | 2019 | |
| Sobi, INC | $55.78 | 2019-2021 | |
| Pfizer INC. | $54.21 | 2023-2025 | |
| Biomerieux INC | $44.26 | 2023-2025 | |
| Neos Therapeutics, LP | $43.98 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $42.49 | 2021-2024 | Crysvita |
| Biomarin Pharmaceutical INC. | $42.16 | 2024-2025 | Voxzogo 1.2mg |
| Takeda Pharmaceuticals U.S.A., INC. | $40.95 | 2020-2022 | |
| Neurelis, INC. | $34.13 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $33.34 | 2024 | |
| Phadia US INC. | $31.79 | 2022-2023 | Immunocap |
| Abbott Laboratories | $28.38 | 2022-2024 | Freestyle Libre 3 |
| Jazz Pharmaceuticals INC. | $27.15 | 2024 | |
| Cipher Pharmaceuticals US LLC | $24.69 | 2025 | Spinosad, Natroba |
| Ironwood Pharmaceuticals, INC | $22.00 | 2024 | |
| Beta Bionics, INC. | $17.36 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Arbor Pharmaceuticals, INC. | $16.54 | 2021 | |
| Tandem Diabetes Care, INC. | $15.54 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar Pharmaceuticals, INC. | $15.52 | 2022 | |
| Adlon Therapeutics L.P. | $14.22 | 2019 | |
| Medtronic, INC. | $14.02 | 2023 | Inpen Smart Insulin Delivery System |
| Cepheid | $13.86 | 2025 | Genexpert |
| Sequel Med Tech, LLC | $13.63 | 2025 | Twiist |
| Genentech USA, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenan Qin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.